What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
Irving L. Weissman mainly focuses on Stem cell, Immunology, Haematopoiesis, Cell biology and Progenitor cell.
His Stem cell research is multidisciplinary, relying on both Molecular biology, Cellular differentiation, Adult stem cell and Bone marrow.
His Molecular biology study combines topics in areas such as T cell, Gene, Cell adhesion molecule and B cell.
His biological study spans a wide range of topics, including Cancer and Cancer research.
As a part of the same scientific study, Irving L. Weissman usually deals with the Haematopoiesis, concentrating on Myeloid and frequently concerns with Dendritic cell homeostasis and Lymphopoiesis.
His research in Cell biology intersects with topics in Telomere, Embryonic stem cell and Genetics.
His most cited work include:
- Stem cells, cancer, and cancer stem cells (7759 citations)
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes (3517 citations)
- Purification and Characterization of Mouse Hematopoietic Stem Cells (2510 citations)
What are the main themes of his work throughout his whole career to date?
Stem cell, Immunology, Cell biology, Haematopoiesis and Progenitor cell are his primary areas of study.
His Stem cell research incorporates themes from Cancer research, Cellular differentiation, Adult stem cell, Bone marrow and Transplantation.
Irving L. Weissman combines topics linked to Cytotoxic T cell with his work on Immunology.
Irving L. Weissman interconnects Endothelial stem cell, Embryonic stem cell, Induced pluripotent stem cell and Cell in the investigation of issues within Cell biology.
The various areas that Irving L. Weissman examines in his Haematopoiesis study include Myeloid, Molecular biology, Hematopoietic stem cell transplantation and Myeloid leukemia.
His Molecular biology research is multidisciplinary, incorporating elements of T cell, Gene and B cell.
He most often published in these fields:
- Stem cell (36.90%)
- Immunology (36.83%)
- Cell biology (33.11%)
What were the highlights of his more recent work (between 2013-2021)?
- Cell biology (33.11%)
- Cancer research (17.24%)
- CD47 (8.20%)
In recent papers he was focusing on the following fields of study:
Irving L. Weissman focuses on Cell biology, Cancer research, CD47, Immunology and Stem cell.
Irving L. Weissman studies Progenitor cell, a branch of Cell biology.
Irving L. Weissman combines subjects such as Stromal cell, Pathology and Cellular differentiation with his study of Progenitor cell.
His Cancer research research is multidisciplinary, relying on both Cancer cell, Cancer, Metastasis, Cancer stem cell and Cancer immunotherapy.
Irving L. Weissman is studying Haematopoiesis, which is a component of Stem cell.
His Haematopoiesis research incorporates elements of Myeloid and Bone marrow.
Between 2013 and 2021, his most popular works were:
- New tools for studying microglia in the mouse and human CNS. (784 citations)
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity (634 citations)
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission (460 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
The scientist’s investigation covers issues in Cell biology, Immunology, CD47, Cancer research and Stem cell.
Irving L. Weissman mostly deals with Progenitor cell in his studies of Cell biology.
His studies in Progenitor cell integrate themes in fields like Cell cycle, Cartilage, Cellular differentiation and Regeneration.
The concepts of his Immunology study are interwoven with issues in Haematopoiesis, Hematopoietic stem cell and Transplantation.
His Cancer research research is multidisciplinary, incorporating perspectives in Lung cancer, Phagocytosis and Transgene.
His Stem cell study focuses on Stem cell theory of aging in particular.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
